Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.83 |
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.51 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.51 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.51 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.51 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.51 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.51 |
| ▸ | DRD1 known ✓ | P21728 | 2/20 | 0.51 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.51 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.51 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.51 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.51 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.51 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.51 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.49 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.49 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL4143302 | 0.95 | DRD2 (0.87) | DRD2CHRM1DRD3LMNACHRM2 | |
| SCHEMBL8311 | 0.91 | DRD2 (1.00) | DRD2CHRM1DRD3LMNACHRM2 | |
| SCHEMBL29368614 | 0.91 | DRD2 (1.00) | DRD2CHRM1DRD3LMNACHRM2 | |
| Hydrochloric Acid SCHEMBL1943859 | 0.90 | DRD2 (0.97) | DRD2CHRM1DRD3LMNACHRM2 | |
| Hydrochloric Acid SCHEMBL8507 | 0.90 | DRD2 (0.97) | DRD2CHRM1DRD3LMNACHRM2 | |
| Phosphoric Acid SCHEMBL4151583 | 0.89 | DRD2 (0.85) | DRD2CHRM1DRD3LMNACHRM2 | |
| SCHEMBL2159879 | 0.83 | DRD2 (0.74) | DRD2CHRM1DRD3LMNACHRM2 | |
| SCHEMBL8022151 | 0.81 | DRD2 (0.80) | DRD2CHRM1DRD3LMNACHRM2 | |
| SCHEMBL12395990 | 0.81 | DRD2 (0.74) | DRD2CHRM1DRD3LMNACHRM2 | |
| SCHEMBL7904011 | 0.79 | DRD2 (0.64) | DRD2HRH4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069291-A1 | Salt Forms | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069291-A1 | Salt Forms | SLC5A1, SLC5A11, SLC5A2 | DRD2 836/4885CHRM1 3028/4885DRD3 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.